Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of Formula (I):



I

wherein:

each R is independently alkyl or cycloalkylalkyl;

R^1 and R^2 are, independently of each other:

(i) hydrogen;

(ii) alkyl; or

(iii) $-COR^3$ wherein R^3 is selected from the group consisting of alkyl, amino, monosubstituted amino, disubstituted amino, or alkyl substituted with one, two or three substituents selected from the group consisting of amino, monosubstituted amino, disubstituted amino, guanidino, amidino, aminoacyl, $-NHCOR^a$ (wherein R^a is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substitutedheteroaryl, heteroaralkyl, or substituted heteroaralkyl), $-NHCONHR^a$ (wherein R^a is as defined above), aryl, substituted aryl, heteroaryl, substituted heteroaryl, carboxy, alkoxycarbonyl, and $-OR^b$ (where R^b is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl,

heteroaralkyl, or substituted heteroaralkyl), provided that at least one of R^1 and R^2 is a group that can form a pharmaceutically acceptable acid addition salt;

n and m are independently an integer from 0 to 4; and

L is:

(i) alkylene or cycloalkylene;

(ii) alkylene substituted with one, two or three substituent(s) selected from the group consisting of aryl, -CONHR^4 (wherein R^4 is hydrogen, alkyl, substituted alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl, heterocyclic, substituted heterocyclic, heterocyclicalkyl, heteroarylthioalkyl, or $-(CHR^5)_{n1}$-CO-(NH-Ar^3-CO)$_m$-NH-Ar^4-CO-NHR^3 where n1 is 1 to 3, R^5 is hydrogen or alkyl, substituted alkyl, and ~~Ar^3~~, m, ~~Ar^4~~, and R^3 are as defined above), -CONHNHR^6 [wherein R^6 is alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, -COR^7, -COOR^8 (wherein R^7 and R^8 are independently of each other alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, or heteroaralkyl), heteroaryl, or heteroaralkyl], -NHR^9 (wherein R^9 is hydrogen, alkyl, substituted alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminoalkylcarbonyl, or heterocycliccarbonyl), and guanidino; or

(iii) -(alkylene)$_x$-Z-(alkylene)$_y$-(Z^a)$_z$- wherein x, y and z are independently 0, 1, or 2 and Z and Z^a are, independently of each other, phenylene, cycloalkylene optionally fused to one or two phenylene ring(s), heterocyclene, -O-, -S-, -NR^{10}- [wherein R^{10} is hydrogen, alkyl, substituted alkyl, cycloalkylcarbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl,-CONHR^4, -COR^7, -COOR^8 (where R^4, R^7 and R^8 are as defined above), -SO_2R^{11} (where R^{11} is alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl) or -$(CHR^5)_{n2}$-NH-(CO-Ar^3-NH)$_m$-CO-Ar^4-NHR^2 where n2 is 2 to 4, R^5 is hydrogen, alkyl, or substituted alkyl, and ~~Ar^3~~, m, ~~Ar^4~~, and R^2 are as defined above], -CO-NH-, or -NH-CO-, provided that

when Z and/or Z^a is $-NR^{10}-$ then it is separated from another nitrogen atom by at least two carbon atoms;

Ar^3, and Ar^4 are independently selected from the group consisting of arylene, substituted arylene, and optionally substituted heteroarylene; and

or a pharmaceutically acceptable salt thereof.

2. (canceled)

3. (Currently Amended) A compound of the formula:



R^1 and R^2 are, independently of each other:

(i) hydrogen;

(ii) alkyl; or

(iii) $-COR^3$ wherein R^3 is selected from the group consisting of alkyl, amino, monosubstituted amino, disubstituted amino, or alkyl substituted with one, two or three substituents selected from the group consisting of amino, monosubstituted amino, disubstituted amino, guanidino, amidino, aminoacyl, $-NHCOR^a$ (wherein R^a is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl), $-NHCONHR^a$ (wherein R^a is as defined above), aryl, substituted aryl, heteroaryl, substituted heteroaryl, carboxy, alkoxycarbonyl, and $-OR^b$ (where R^b is hydrogen,

alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl), provided that at least one of R^1 and R^2 is a group that can form a pharmaceutically acceptable acid addition salt;

n and m are independently an integer from 0 to 4; and

L is:

(i) alkylene or cycloalkylene;

(ii) alkylene substituted with one, two or three substituent(s) selected from the group consisting of aryl, -CONHR^4 (wherein R^4 is hydrogen, alkyl, substituted alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl, heterocydic, substituted heterocyclic, heterocyclicalkyl, heteroarylthioalkyl, or –$(CHR^5)_{n1}$-CO-(NH-Ar^3-CO)$_m$-NH-Ar^4-CO-NHR^3 where n1 is 1 to 3, R^5 is hydrogen or alkyl, substituted alkyl, and ~~Ar^3~~, m, ~~Ar^4~~, and R^3 are as defined above), -CONHNHR^6 [wherein R^6 is alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, -COR^7, -COOR^8 (wherein R^7 and R^8 are independently of each other alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, or heteroaralkyl), heteroaryl, or heteroaralkyl], -NHR^9 (wherein R^9 is hydrogen, alkyl, substituted alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminoalkylcarbonyl, or heterocycliccarbonyl), and guanidino; or

(iii) -(alkylene)$_x$-Z-(alkylene)$_y$-$(Z^a)_z$- wherein x, y and z are independently 0, 1, or 2 and Z and Z^a are, independently of each other, phenylene, cycloalkylene optionally fused to one or two phenylene ring(s), heterocyclene, -O-, -S-, -NR^{10}- [wherein R^{10} is hydrogen, alkyl, substituted alkyl, cycloalkylcarbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl,-CONHR^4, -COR^7, -COOR^8 (where R^4, R^7 and R^8 are as defined above), -SO_2R^{11} (where R^{11} is alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl) or -$(CHR^5)_{n2}$-NH-(CO-Ar^3-NH)$_m$-CO-Ar^4-NHR^2 where n2 is 2 to 4, R^5 is hydrogen, alkyl, or substituted alkyl, and ~~Ar^3~~, m, ~~Ar^4~~, and R^2 are as defined above], -CO-NH-, or -NH-CO-, provided that

when Z and/or Z^a is $-NR^{10}-$ then it is separated from another nitrogen atom by at least two carbon atoms;

Ar^3, and Ar^4 are independently selected from the group consisting of arylene, substituted arylene, and optionally substituted heteroarylene; and

or a pharmaceutically acceptable salt thereof.

4. (Previously Presented) The compound of Claim 1 wherein n and m are 0 or 1.

5. (canceled)

6. (Previously Presented) The compound of Claim 1 wherein R^1 and R^2 are independently $-COR^3$.

7. (Previously Presented) The compound of Claim 6 wherein R^1 and R^2 are independently aminomethylcarbonyl, 1-amino-4-guanidinobutylcarbonyl, 1,4-diaminobutylcarbonyl, 1,5-diaminopentyl-carbonyl, 1-amino-5-(3,4difluorophenylureido)-pentylcarbonyl, 1-(3,4-difluoro-phenylureido)-4-guanidinobutylcarbonyl, 1-[4-(N,N-(2-chloroethyl)-aminophenylbutanoyl)]amino-4-guanidinobutylcarbonyl, or 1-amino-5-[4-(N,N-(2-chloroethyl)-aminophenyl-butanoyl)]aminopentylcarbonyl.

8. (Previously Presented) A compound of the Formula (I):



I

wherein:

each R is independently alkyl or cycloalkylalkyl;

R^1 and R^2 are, independently of each other:

(i) hydrogen;

(ii) alkyl; or

(iii) $-COR^3$ wherein R^3 is selected from the group consisting of alkyl, amino, monosubstituted amino, disubstituted amino, or alkyl substituted with one, two or three substituents selected from the group consisting of amino, monosubstituted amino, disubstituted amino, guanidino, amidino, aminoacyl, $-NHCOR^a$ (wherein R^a is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl), $-NHCONHR^a$ (wherein R^a is as defined above), aryl, substituted aryl, heteroaryl, substituted heteroaryl, carboxy, alkoxycarbonyl, and $-OR^b$ (where R^b is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl), provided that at least one of R^1 and R^2 is a group that can form a pharmaceutically acceptable acid addition salt;

n and m are independently an integer from 0 to 4; and

L is alkylene;

or a pharmaceutically acceptable salt thereof.

9. (Previously Presented) The compound of Claim 8 wherein L is 1,2-ethylene, 1,3-propylene, 1,4-butylene, 1,6-hexylene, 1,8-octylene, 1,12-dodecylene, 1-methylethylene, or 1,2-hexadecylene.

10. (Currently Amended) A compound of the Formula (I):



I

wherein:

each R is independently alkyl or cycloalkylalkyl;

R^1 and R^2 are, independently of each other:

(i) hydrogen;

(ii) alkyl; or

(iii) $-COR^3$ wherein R^3 is selected from the group consisting of alkyl, amino, monosubstituted amino, disubstituted amino, or alkyl substituted with one, two or three substituents selected from the group consisting of amino, monosubstituted amino, disubstituted amino, guanidino, amidino, aminoacyl, $-NHCOR^a$ (wherein R^a is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl), $-NHCONHR^a$ (wherein R^a is as defined above), aryl, substituted aryl, heteroaryl, substituted heteroaryl, carboxy, alkoxycarbonyl, and $-OR^b$ (where R^b is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl,

heteroaralkyl, or substituted heteroaralkyl), provided that at least one of R^1 and R^2 is a group that can form a pharmaceutically acceptable acid addition salt;

n and m are independently an integer from 0 to 4; and

L is alkylene substituted with one, two or three substituent(s) selected from the group consisting of aryl, -CONHR^4 (wherein R^4 is hydrogen, alkyl, substituted alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl, heterocyclic, substituted heterocyclic, heterocyclicalkyl, heteroarylthioalkyl, or–$(CHR^5)_{n1}$-CO-$(NH\text{-}Ar^3\text{-}CO)_m$-NH-$Ar^4$-CO-$NHR^3$ where n1 is 1 to 3, R^5 is hydrogen or alkyl, substituted alkyl, and ~~Ar^3~~, m, ~~Ar^4~~, and R^3 are as defined above), -CONHNHR^6 [wherein R^6 is alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, -COR^7, -COOR^8 (wherein R^7 and R^8 are independently of each other alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, or heteroaralkyl), heteroaryl, or heteroaralkyl], -NHR^9 (wherein R^9 is hydrogen, alkyl, substituted alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminoalkylcarbonyl, or heterocycliccarbonyl), and guanidino;

Ar^3, and Ar^4 are independently selected from the group consisting of arylene, substituted arylene, and optionally substituted heteroarylene; and

or a pharmaceutically acceptable salt thereof.

11. (Previously Presented) The compound of Claim 10 wherein L is meso-1,2-diphenylethylene, 1-(p-nitrophenylaminocarbonyl)-1,5-pentylene, 1-(napth-2-ylaminocarbonyl)-1,5pentylene, 1-(pentafluorophenylhydrazidocarbonyl)-1,5-pentylene, 1-(5-trifluoro-pyrimidin-2-ylhydrazidocarbonyl)-1,5-pentylene, 1-(2-pyrene-lylethylamino-carbonyl)-1,5-pentylene, 1-[2-(6-nitrobenzimidazol-1-ylethylaminocarbonyl]-1,5-pentylene, 1-[2-(indol-3-yl)-ethylaminocarbonyl]-1,5-pentylene, 1-[2-(5-fluoroindol-3-yl)ethylaminocarbonyl]-1,5-pentylene, 1-[2-(4-nitrophenyl)ethylaminocarbonyl]-1,5-pentylene, 1-(benzyloxycarbonyl-hydrazidocarbonyl)-1,2-ethylene, 1-(napth-l-ylaminocarbonyl)-1,5-pentylene, 1-(4-pyrene-1-ylbutylaminocarbonyl)-1,5-pentylene, l-(2-(2-

trifluoromethylquinolin-4-yl)thio-ethylaminocarbonyl)-1,5-pentylene, 1-(pentafluorophenylhydrazidocarbonyl)-1,4-butylene, 1-(4-pyrene-1-ylmethylaminocarbonyl)-1,5-pentylene, 1-(2-hydroxyethylaminocarbonyl)-1,5-pentylene, 1-(2-aminoethylaminocarbonyl)-1,5-pentylene, 1-(3-dimethylaminopropyl-aminocarbonyl)-1,5-pentylene, 1-(bis-(2-aminoethyl)aminoethylaminocarbonyl)-1,5-pentylene, 1-(N-(2-aminoethyl)aminoethylaminocarbonyl)-1,5-pentylene, 2-(aminomethylcarbonyl-amino)-1,3-propylene, or 2-(3-hydroxypyrrolidin-5-ylcarbonyl-amino)-1,3-propylene.

12. (Currently Amended) A compound of the Formula (I):



I

wherein:

each R is independently alkyl or cycloalkylalkyl;

R^1 and R^2 are, independently of each other:

(i) hydrogen;

(ii) alkyl; or

(iii) $-COR^3$ wherein R^3 is selected from the group consisting of alkyl, amino, monosubstituted amino, disubstituted amino, or alkyl substituted with one, two or three substituents selected from the group consisting of amino, monosubstituted amino, disubstituted amino, guanidino, amidino, aminoacyl, $-NHCOR^a$ (wherein R^a is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or

substituted heteroaralkyl), -NHCONHR^a (wherein R^a is as defined above), aryl, substituted aryl, heteroaryl, substituted heteroaryl, carboxy, alkoxycarbonyl, and -OR^b (where R^b is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl), provided that at least one of R^1 and R^2 is a group that can form a pharmaceutically acceptable acid addition salt;

n and m are independently an integer from 0 to 4; and

L is -(alkylene)$_x$-Z-(alkylene)$_y$-(Z^a)$_z$- wherein x, y and z are independently 0, 1, or 2 and Z and Z^a are, independently of each other, phenylene, cycloalkylene optionally fused to one or two phenylene ring(s), heterocyclene, -O-, -S-, -NR^{10}- [wherein R^{10} is hydrogen, alkyl, substituted alkyl, cycloalkylcarbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl,-CONHR^4, -COR^7, -COOR^8 (where R^4, R^7 and R^8 are as defined above), -SO$_2$R^{11} (where R^{11} is alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl) or -(CHR^5)$_{n2}$-NH-(CO-Ar^3-NH)$_m$-CO-Ar^4-NHR^2 where n2 is 2 to 4, R^5 is hydrogen, alkyl, or substituted alkyl, and ~~Ar^3~~, m, ~~Ar^4~~, and R^2 are as defined above], -CO-NH-, or -NH-CO-,

Ar^3, and Ar^4 are independently selected from the group consisting of arylene, substituted arylene, and optionally substituted heteroarylene; and

provided that when Z and/or Z^a is –NR^{10}- then it is separated from another nitrogen atom by at least two carbon atoms;

or a pharmaceutically acceptable salt thereof.

13. (Previously Presented) The compound of Claim 12 wherein L is m-xylene, p-xylene, 2,7-fluorendiyl, *bis*-(3-N-benzyloxycarbonylamino)propylene [-(CH$_2$)$_3$-N(BzOCO-)-(CH$_2$)$_3$-], *bis*-(2-napth-2-ylsulfonylamino)ethylene [-(CH$_2$)$_2$-N(-SO$_2$napth-2-yl)-(CH$_2$)$_2$-], *bis*-(2-N-3,5-dinitrophenylcarbonylamino)ethylene [-(CH$_2$)$_2$-N(-CO-3,5-dinitrophenyl)-(CH$_2$)$_2$-], 1,3-cyclohexyl-bis-methylene [-(CH$_2$)-(1,3-C$_6$H$_{10}$)-(CH$_2$)-], 1,4-cyclohexyl-bis-methylene [-(CH$_2$)-

(1,4-C_6H_{10})-(CH_2)-], 4,4'-methylene-bis-1,4-cyclohexylene [-(1,4-C_6H_{10})-(CH_2)-(1,4-C_6H_{10})-], 1,2-cyclohexylene (1,2-C_6H_{10}-), *bis*-(2-adamantyll-ylcarbonylamino)ethylene, *bis*-(3-N-methylamino)propylene [-$(CH_2)_3$-N(-CH_3)-$(CH_2)_3$-], *bis*-(3-amino)propylene [-$(CH_2)_3$-NH-$(CH_2)_3$-], 1,4-piperazino- *bis*-propylene [-$(CH_2)_3$-(1,4-piperazino)-$(CH_2)_3$-] , *bis*-(2-(2-aminoethyl)amino)ethylene [-$(CH_2)_2$-N(-$(CH_2)_2NH_2$)-$(CH_2)_2$-], and *bis*-(2-amino)ethylene [-$(CH_2)_2$-NH-$(CH_2)_2$-] .

14. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claims 1, 3-4 and 6-13 and a pharmaceutically suitable carrier.

15-19. (canceled)

20. (Previously Presented) A compound of claim 1 which compound is represented by formula (VII)



(VII)

wherein

L is selected from the group consisting of alkylene and cycloalkylene;

A is an amino acid side chain; and

R^{23} is selected from the group consisting of guanidino, amino, and ornithylamino.

21. (Previously Presented) A compound of claim 20 selected from the group consisting of



174



177



173



169



171



170



172

and pharmaceutically acceptable salts thereof.

22. (canceled)